474 related articles for article (PubMed ID: 17257673)
1. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.
Valent P; Horny HP; Bennett JM; Fonatsch C; Germing U; Greenberg P; Haferlach T; Haase D; Kolb HJ; Krieger O; Loken M; van de Loosdrecht A; Ogata K; Orfao A; Pfeilstöcker M; Rüter B; Sperr WR; Stauder R; Wells DA
Leuk Res; 2007 Jun; 31(6):727-36. PubMed ID: 17257673
[TBL] [Abstract][Full Text] [Related]
2. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions.
Valent P; Horny HP
Eur J Clin Invest; 2009 Jul; 39(7):548-53. PubMed ID: 19453651
[TBL] [Abstract][Full Text] [Related]
3. A comparative review of classification systems in myelodysplastic syndromes (MDS).
Bennett JM
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
[TBL] [Abstract][Full Text] [Related]
4. Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop.
Platzbecker U; Santini V; Mufti GJ; Haferlach C; Maciejewski JP; Park S; Solé F; van de Loosdrecht AA; Haase D
Leuk Res; 2012 Mar; 36(3):264-70. PubMed ID: 22137318
[TBL] [Abstract][Full Text] [Related]
5. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.
Valent P; Akin C; Escribano L; Födinger M; Hartmann K; Brockow K; Castells M; Sperr WR; Kluin-Nelemans HC; Hamdy NA; Lortholary O; Robyn J; van Doormaal J; Sotlar K; Hauswirth AW; Arock M; Hermine O; Hellmann A; Triggiani M; Niedoszytko M; Schwartz LB; Orfao A; Horny HP; Metcalfe DD
Eur J Clin Invest; 2007 Jun; 37(6):435-53. PubMed ID: 17537151
[TBL] [Abstract][Full Text] [Related]
6. World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes.
Schiffer CA
Semin Hematol; 2008 Jan; 45(1):3-7. PubMed ID: 18179963
[TBL] [Abstract][Full Text] [Related]
7. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface.
Wimazal F; Fonatsch C; Thalhammer R; Schwarzinger I; Müllauer L; Sperr WR; Bennett JM; Valent P
Leuk Res; 2007 Nov; 31(11):1461-8. PubMed ID: 17507091
[TBL] [Abstract][Full Text] [Related]
8. Prognostic scoring systems for risk assessment in myelodysplastic syndromes.
Greenberg PL; Sanz GF; Sanz MA
Forum (Genova); 1999; 9(1):17-31. PubMed ID: 10101208
[TBL] [Abstract][Full Text] [Related]
9. Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS).
Fenaux P
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S11-5. PubMed ID: 16085012
[TBL] [Abstract][Full Text] [Related]
10. Pediatric myelodysplastic syndromes.
Rytting ME
Curr Hematol Rep; 2004 May; 3(3):173-7. PubMed ID: 15087064
[TBL] [Abstract][Full Text] [Related]
11. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
[TBL] [Abstract][Full Text] [Related]
12. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS.
Valent P; Bain BJ; Bennett JM; Wimazal F; Sperr WR; Mufti G; Horny HP
Leuk Res; 2012 Jan; 36(1):1-5. PubMed ID: 21920601
[TBL] [Abstract][Full Text] [Related]
13. Evolving classifications of the myelodysplastic syndromes.
Komrokji RS; Bennett JM
Curr Opin Hematol; 2007 Mar; 14(2):98-105. PubMed ID: 17255786
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts.
Mufti GJ; Bennett JM; Goasguen J; Bain BJ; Baumann I; Brunning R; Cazzola M; Fenaux P; Germing U; Hellström-Lindberg E; Jinnai I; Manabe A; Matsuda A; Niemeyer CM; Sanz G; Tomonaga M; Vallespi T; Yoshimi A;
Haematologica; 2008 Nov; 93(11):1712-7. PubMed ID: 18838480
[TBL] [Abstract][Full Text] [Related]
15. Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes.
Aul C; Giagounidis A; Heinsch M; Germing U; Ganser A
Rev Clin Exp Hematol; 2004 Dec; 8(2):E1. PubMed ID: 16027099
[TBL] [Abstract][Full Text] [Related]
16. The evolving clinical scenario of myelodysplastic syndrome: the need for a complete and up to date upfront diagnostic assessment.
Pilo F; Di Tucci AA; Dessalvi P; Caddori A; Angelucci E
Eur J Intern Med; 2010 Dec; 21(6):490-5. PubMed ID: 21111932
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes.
Foran JM; Shammo JM
Am J Med; 2012 Jul; 125(7 Suppl):S6-13. PubMed ID: 22735753
[TBL] [Abstract][Full Text] [Related]
18. Novel therapies for myelodysplastic syndromes.
Faderl S; Kantarjian HM
Cancer; 2004 Jul; 101(2):226-41. PubMed ID: 15241818
[TBL] [Abstract][Full Text] [Related]
19. [Myelodysplastic syndromes].
Paladini G; Pecorari P; De Sabbata G; Sammartini C
Recenti Prog Med; 2004 Feb; 95(2):108-19. PubMed ID: 15072397
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of myelodysplastic syndromes in cytopenic patients.
Wang SA
Hematol Oncol Clin North Am; 2011 Oct; 25(5):1085-110, vii. PubMed ID: 22054736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
